Consensus Hims & Hers Health, Inc.

Equities

HIMS

US4330001060

Market Closed - Nyse Other stock markets 16:00:02 2024-04-26 EDT			5-day change	1st Jan Change
12.5 ^USD	+1.87%		+5.04%	+40.45%

04-26	Seaport Global Starts Hims & Hers Health With Buy Rating	MT
04-16	Jefferies Downgrades Hims & Hers Health to Hold From Buy, Cuts Price Target to $15 From $17	MT

Evolution of the average Target Price on Hims & Hers Health, Inc.

Price target over the last 5 years

History of analyst recommendation changes

015680070f1.ymbgFMCp0tDxModdE4PV2pCUppNb3krvmtIrt4viMXY.hlCCbvnd4r-uSsBocM6f7Kny39EXthCmqKZa48KTd0abANhfkNuCs6BI9A~fd348ddb799f16984558d699f94ac791

Analyst Recommendations on Hims & Hers Health, Inc.

Seaport Global Starts Hims & Hers Health With Buy Rating	04-26	MT
Jefferies Downgrades Hims & Hers Health to Hold From Buy, Cuts Price Target to $15 From $17	04-16	MT
Canaccord Genuity Initiates Coverage on Hims & Hers Health With Buy Rating, $20 Price Target	04-10	MT
Hims & Hers Health Insider Sold Shares Worth $823,055, According to a Recent SEC Filing	03-22	MT
Tigress Financial Boosts Price Target on Hims & Hers Health to $19 From $15, Cites Move to Accelerated Growth Phase, Keeps Buy Rating	03-01	MT
Piper Sandler Adjusts Price Target on Hims & Hers Health to $11 From $9, Maintains Neutral Rating	02-27	MT
Deutsche Bank Adjusts Hims & Hers Health Price Target to $14 From $8, Maintains Hold Rating	02-27	MT
Truist Securities Adjusts Price Target on Hims & Hers Health to $13 From $10, Keeps Hold Rating	02-27	MT
Leerink Partners Initiates Coverage on Hims & Hers Health With Market Perform Rating, $10 Price Target	02-26	MT
Tigress Financial Raises Price Target on Hims & Hers Health to $15 From $14, Maintains Buy Rating	01-05	MT
Deutsche Bank Adjusts Hims & Hers Health Price Target to $8 From $11, Maintains Hold Rating	11-08	MT
Truist Securities Cuts Price Target on Hims & Hers Health to $10 From $12, Maintains Hold Rating	23-08-09	MT
TD Cowen Starts Hims & Hers Health at Outperform With $11 Price Target	23-07-28	MT
Tigress Financial Adjusts Hims & Hers Health Price Target to $14 From $12 Due to Ongoing Growth, Penetration in Core Markets, Maintains Buy Rating	23-06-15	MT
Tigress Financial Adjusts Hims & Hers Health Price Target to $14 From $12, Maintains Buy Rating	23-06-15	MT
Piper Sandler Adjusts Price Target on Hims & Hers Health to $11 From $12, Keeps Neutral Rating	23-05-30	MT
Deutsche Bank Adjusts Hims & Hers Health Price Target to $11 From $9, Maintains Hold Rating	23-05-10	MT
BofA Securities Adjusts Hims & Hers Health's Price Target to $15 From $13.50, Keeps Buy Rating	23-05-09	MT
Piper Sandler Adjusts Price Target on Hims & Hers Health to $12 From $10, Keeps Neutral Rating	23-05-09	MT
Guggenheim Adjusts Price Target on Hims & Hers Health to $18 From $15, Maintains Buy Rating	23-04-27	MT
Baird Initiates Hims & Hers Health at Neutral	23-04-11	MT
Deutsche Bank Adjusts Hims & Hers Health Price Target to $9 From $7, Maintains Hold Rating	23-03-01	MT
Credit Suisse Raises Hims & Hers Health's Price Target to $14 From $8 After Higher-Than-Expected Q4 Results, Keeps Outperform Rating	23-03-01	MT
Piper Sandler Adjusts Price Target on Hims & Hers Health to $10 From $7, Maintains Neutral Rating	23-02-28	MT
Truist Securities Adjusts Price Target on Hims & Hers Health to $12 From $7, Maintains Hold Rating	23-02-28	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

12.5 USD

Average target price

15.52 USD

Spread / Average Target

+24.14%

High Price Target

23 USD

Spread / Highest target

+84.00%

Low Price Target

7 USD

Spread / Lowest Target

-44.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Hims & Hers Health, Inc.

Seaport Global Securities
Jefferies & Co.
Canaccord Genuity
Tigress Financial
Deutsche Bank Securities
Piper Sandler
Truist Securities
Leerink Partners
TD Cowen
BofA Securities
Guggenheim
Baird
Credit Suisse
Citigroup
SVB Securities LLC

Ratings for Hims & Hers Health, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar